

General Assembly

January Session, 2021

# Substitute Bill No. 847

## AN ACT CONCERNING NEWBORN INFANT HEALTH SCREENING.

Be it enacted by the Senate and House of Representatives in General Assembly convened:

Section 1. Section 19a-55 of the general statutes is repealed and the
following is substituted in lieu thereof (*Effective October 1, 2021*):

3 (a) The administrative officer or other person in charge of each 4 institution caring for newborn infants, or a nurse-midwife licensed pursuant to chapter 377 or midwife shall cause to have administered to 5 6 every such newborn infant in its care an HIV-related test, as defined in 7 section 19a-581, a test for [phenylketonuria and other metabolic 8 diseases] amino acid disorders, including phenylketonuria, organic acid 9 disorders, fatty acid oxidation disorders, including, but not limited to, 10 long-chain 3-hydroxyacyl CoA dehydrogenase (L-CHAD) and 11 medium-chain acyl-CoA dehydrogenase (MCAD), hypothyroidism, 12 galactosemia, sickle cell disease, maple syrup urine disease, 13 homocystinuria, biotinidase deficiency, congenital adrenal hyperplasia, 14 severe combined immunodeficiency disease, adrenoleukodystrophy 15 and such other tests for [inborn errors of metabolism as shall be] other 16 metabolic and genetic disorders included on the recommended uniform 17 screening panel pursuant to 42 USC 300b-10, as amended from time to 18 time, as prescribed by the [Department] Commissioner of Public Health. 19 The tests shall be administered as soon after birth as is medically

## 20 appropriate.]

21 (b) The testing requirements prescribed in subsection (a) of this 22 section shall be performed using a blood spot specimen. The blood spot 23 specimen shall be collected not earlier than twenty-four hours after the 24 birth of the newborn infant and not later than forty-eight hours after the 25 birth of such infant, unless the institution caring for newborn infants, 26 nurse-midwife licensed pursuant to chapter 377 or midwife determines 27 that a situation exists to warrant an early collection of the specimen or if 28 collection of the specimen is medically contraindicated. Situations that warrant early collection of the specimen shall include, but shall not be 29 30 limited to, the imminent transfusion of blood products, dialysis, early 31 discharge of the newborn infant from the institution, transfer of the 32 newborn infant to another institution or imminent death. If the newborn 33 infant dies before a blood spot specimen can be obtained, the specimen shall be collected as soon as practicable after death. The institution 34 35 licensed to care for newborn infants, nurse-midwife or midwife shall notify the Department of Public Health when a specimen is not collected 36 within forty-eight hours after the birth of such infant due to: (1) The 37 38 infant's medical fragility, (2) refusal by the parents when newborn infant 39 screening is in conflict with their religious tenets and practice, (3) the 40 newborn infant receiving comfort measures only, or (4) any other 41 reason. Such notification shall be documented in the department's 42 newborn screening system pursuant to section 19a-53 by the institution caring for newborn infants, nurse-midwife or midwife, or sent in 43 44 writing to the department not later than seventy-two hours after the birth of the newborn infant. The institution caring for newborn infants, 45 nurse-midwife or midwife shall send the blood spot specimen to the 46 47 state public health laboratory not later than twenty-four hours after the time of collection. The department may request an additional blood spot 48 49 specimen if: (A) There was an early collection of the specimen, (B) the specimen was collected following a transfusion of blood products, (C) 50 51 the specimen is unsatisfactory for testing, or (D) the department determines that there is an abnormal result. If the mother has had an 52 53 HIV-related test pursuant to section 19a-90 or 19a-593, the person

54 responsible for testing under this section may omit an HIV-related test.

55 (c) The Commissioner of Public Health shall (1) administer the 56 newborn screening program, (2) direct persons identified through the 57 screening program to appropriate specialty centers for treatments, 58 consistent with any applicable confidentiality requirements, and (3) set 59 the fees to be charged to institutions to cover all expenses of the 60 comprehensive screening program including testing, tracking and 61 treatment. The fees to be charged pursuant to subdivision (3) of this 62 subsection shall be set at a minimum of ninety-eight dollars. The 63 Commissioner of Public Health shall publish a list of all the abnormal 64 conditions for which the department screens newborns under the 65 newborn screening program. [, which shall include screening for amino 66 acid disorders, organic acid disorders, fatty acid oxidation disorders, 67 including, but not limited to, long-chain 3-hydroxyacyl CoA 68 dehydrogenase (L-CHAD) and medium-chain acyl-CoA 69 dehydrogenase (MCAD), and, subject to the approval of the Secretary 70 of the Office of Policy and Management, any other disorder included on 71 the recommended uniform screening panel pursuant to 42 USC 300b-10, 72 as amended from time to time.]

73 [(b)] (d) In addition to the testing requirements prescribed in 74 subsection (a) of this section, the administrative officer or other person 75 in charge of each institution caring for newborn infants, or a licensed 76 nurse-midwife or midwife, shall cause to have administered to (1) every 77 such infant in its care a screening test for (A) cystic fibrosis, and (B) 78 critical congenital heart disease, [and (C) on and after January 1, 2020, 79 spinal muscular atrophy,] and (2) any newborn infant who fails a 80 newborn hearing screening, as described in section 19a-59, a screening 81 test for cytomegalovirus, provided such screening test shall be 82 administered within available appropriations. The administrative 83 officer or other person in charge of each institution caring for newborn 84 infants who performs the testing for critical congenital heart disease 85 shall enter the results of such test into the newborn screening system 86 pursuant to section 19a-53. The administrative officer or other person in

87 charge of each institution who performs the testing for cystic fibrosis 88 shall report the number of newborn infants screened and the aggregate 89 results of such testing on an annual basis to the Department of Public Health, in a form and manner prescribed by the Commissioner of Public 90 91 Health. The provisions of this subsection shall apply irrespective of the 92 patient's insurance status or source of payment, including self-pay 93 status. Such screening tests shall be administered as soon after birth as 94 is medically appropriate.

95 [(c)] (e) The administrative officer or other person in charge of each 96 institution caring for newborn infants shall report any case of 97 cytomegalovirus that is confirmed as a result of a screening test 98 administered pursuant to subdivision (2) of subsection [(b)] (d) of this 99 section to the Department of Public Health in a form and manner 100 prescribed by the Commissioner of Public Health.

101 [(d)] <u>(f)</u> The provisions of this section shall not apply to any infant 102 whose parents object to the test or treatment as being in conflict with 103 their religious tenets and practice. The commissioner shall adopt 104 regulations, in accordance with the provisions of chapter 54, to 105 implement the provisions of this section.

This act shall take effect as follows and shall amend the following sections:

#### Statement of Legislative Commissioners:

*October* 1, 2021

In Subsec. (a), "<u>nurse-midwife</u>" was changed to "<u>or a nurse-midwife</u>" for clarity, in Subsec. (b) provisions were rewritten and subdivision and subparagraph indicators were added for clarity, and in Subsec. (d) "<u>section</u>" was changed to "<u>subsection</u>" for accuracy.

19a-55

PH Joint Favorable Subst.

**4** of 4

Section 1